CTX TNA2

CTX TNA2 represents a type I astrocyte cell line, derived from primary cultures of type 1 astrocytes sourced from the frontal cortex tissue of neonatal rats. Following an initial plating phase, these cultures underwent transfection with a DNA construct harboring the oncogenic early region of SV40, which was placed under the transcriptional regulation of the human GFAP promoter (pGFA-SV-Tt), along with pPGK-neo featuring the murine phosphoglycerate kinase gene promoter. As a result, CTX TNA2 cells have retained key characteristics consistent with the type 1 astrocyte phenotype. Notably, around 20% of these cells exhibit immunoreactivity for glial fibrillary acidic protein (GFAP), indicating their astrocytic identity. Additionally, they possess a high-affinity gamma-aminobutyric acid (GABA) uptake mechanism, which is susceptible to inhibition by beta-alanine. In terms of protein production, CTX TNA2 cells synthesize alpha 2 macroglobulin at levels similar to those found in primary astrocytes but exhibit markedly reduced transferrin production. Immunostaining analysis further confirms the presence of SV40 T-antigen within the nuclei of over 95% of these cells.

Why choose CTX TNA2 from AcceGen?

CTX TNA2 cells from AcceGen exhibit exceptional viability and quality, having been meticulously cultured under optimal conditions. These cells are delivered in a sterile state, rigorously screened for the absence of bacteria, yeast, mycoplasma, and human pathogens, including HIV, HBV, and HCV. Additionally, they are cryopreserved by skilled operators and undergo stringent quality control measures to ensure their reliability and utility in various research applications.